阿替利珠单抗联合化疗对比安慰剂联合化疗一线治疗局部晚期或转移性尿路上皮癌(IMvigor130):随机对照3期研究的最终总生存分析结果
IMvigor130研究最终分析显示,在局部晚期或转移性尿路上皮癌患者中,阿替利珠单抗联合铂类化疗(A组)对比安慰剂联合铂类化疗(C组)的中位总生存期为16.1个月 vs 13.4个月(分层HR 0.85,95%CI 0.73-1.00;单侧P=0.023),未达到预设显著性边界(单侧P=0.021),无新的安全性信号。
要点
- A组中位OS 16.1个月 vs C组13.4个月,分层HR 0.85(95%CI 0.73-1.00),单侧P=0.023,未达到预设显著性边界0.021。
- A组3-4级治疗相关不良事件最常见为贫血(37% vs 34%)和中性粒细胞减少(37% vs 30%)。
- A组治疗相关死亡9例(2%),C组4例(1%)。
核心结论
- 一线阿替利珠单抗联合铂类化疗的无进展生存获益未转化为意向治疗人群总生存的显著改善。
- 需要进一步研究以了解哪些患者可能从一线联合治疗中获益。
- 未观察到新的安全性信号。
研究设计与样本
- 全球、部分盲法、随机对照3期研究,在35个国家221家医院和肿瘤中心入组。
- 入组初治局部晚期或转移性尿路上皮癌患者,年龄≥18岁,ECOG体能状态评分0-2。
- 按1:1:1随机分配至A组(阿替利珠单抗联合铂类化疗)、B组(阿替利珠单抗单药)或C组(安慰剂联合铂类化疗),按PD-L1状态、Bajorin危险因素评分和研究者选择的铂类化疗分层。
- 2016年7月15日至2018年7月20日共入组并随机分配1213例患者,其中A组451例、C组400例。
- 共同主要终点为意向治疗人群中A组对比C组的研究者评估无进展生存和总生存,以及B组对比C组的总生存,按层级检验;本文报告A组对比C组的最终总生存和更新安全性结局。
主要发现
- 数据截止2022年8月31日,中位随访13.4个月(IQR 6.2-30.8),A组中位总生存16.1个月(95%CI 14.2-18.8;336例死亡)vs C组13.4个月(95%CI 12.0-15.3;310例死亡),分层风险比0.85(95%CI 0.73-1.00),单侧P=0.023。
- A组3-4级治疗相关不良事件:贫血168/454例(37%)vs C组133/389例(34%);中性粒细胞减少167例(37%)vs 115例(30%);中性粒细胞计数降低98例(22%)vs 95例(24%);血小板减少95例(21%)vs 70例(18%);血小板计数降低92例(20%)vs 92例(24%)。
- 严重不良事件:A组243例(54%)vs C组196例(50%)。
- 治疗相关死亡:A组9例(2%;急性肾损伤、呼吸困难、肝衰竭、肝炎、中性粒细胞减少、肺炎、呼吸衰竭、脓毒症和血小板减少各1例)vs C组4例(1%;不明原因死亡、腹泻、发热性中性粒细胞减少和中毒性肝炎各1例)。
关键数值与推荐
- 总生存最终预设显著性边界为单侧P=0.021。
- A组给药方案:每21天周期第1天和第8天静脉给予吉西他滨1000 mg/m2,联合研究者选择的卡铂(曲线下面积4.5 mg/mL/min或5 mg/mL/min,静脉给药)或顺铂(70 mg/m2,静脉给药),每周期第1天静脉给予阿替利珠单抗1200 mg或安慰剂。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以了解哪些患者可能从一线联合治疗中获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: IMvigor130 demonstrated statistically significant investigator-assessed progression-free survival benefit with first-line atezolizumab plus platinum-based chemotherapy (group A) versus placebo plus platinum-based chemotherapy (group C) in patients with locally advanced or metastatic urothelial carcinoma. Overall survival was not improved in interim analyses. Here we report the final overall analysis for group A versus group C. METHODS: In this global, partially blinded, randomised, controlled, phase 3 study, patients (aged ≥18 years) with previously untreated locally advanced or metastatic urothelial cancer and who had an Eastern Cooperative Oncology Group performance status of 0-2 were enrolled at 221 hospitals and oncology centres in 35 countries. Patients were randomly assigned (1:1:1), with a permuted block method (block size of six) and an interactive voice and web response system, stratified by PD-L1 status, Bajorin risk factor score, and investigator's choice of platinum-based chemotherapy, to receive atezolizumab plus platinum-based chemotherapy (group A), atezolizumab monotherapy (group B), or placebo plus platinum-based chemotherapy (group C). Sponsors, investigators, and patients were masked to assignment to atezolizumab or placebo (ie, group A and group C) and atezolizumab monotherapy (group B) was open label. For groups A and C, all patients received gemcitabine (1000 mg/m2 intravenously; day 1 and day 8 of each 21-day cycle), plus investigator's choice of carboplatin (area under curve 4·5 mg/mL per min or 5 mg/mL per min; intravenously) or cisplatin (70 mg/m2 intravenously), plus either atezolizumab (1200 mg intravenously) or placebo on day 1 of each cycle. Co-primary endpoints of the study were investigator-assessed progression-free survival and overall survival for group A versus group C in the intention-to-treat (ITT) population (ie, all randomised patients), and overall survival for group B versus group C, tested hierarchically. Final overall survival and updated safety outcomes (safety population; all patients who received any amount of any study treatment component) for group A versus group C are reported here. The final prespecified boundary for significance of the overall survival analysis was one-sided p=0·021. The trial is registered with ClinicalTrials.gov, NCT02807636, and is active but no longer recruiting. FINDINGS: Between July 15, 2016, and July 20, 2018, 1213 patients were enrolled and randomly assigned to treatment, of whom 851 were assigned to group A (n=451) and group C (n=400). 338 (75%) patients in group A and 298 (75%) in group C were male, 113 (25%) in group A and 102 (25%) in group C were female, and 346 (77%) in group A and 304 (76%) in group C were White. At data cutoff (Aug 31, 2022), after a median follow up of 13·4 months (IQR 6·2-30·8), median overall survival was 16·1 months (95% CI 14·2-18·8; 336 deaths) in group A versus 13·4 months (12·0-15·3; 310 deaths) in group C (stratified hazard ratio 0·85 [95% CI 0·73-1·00]; one-sided p=0·023). The most common grade 3-4 treatment-related adverse events were anaemia (168 [37%] of 454 patients who received atezolizumab plus chemotherapy vs 133 [34%] of 389 who received placebo plus chemotherapy), neutropenia (167 [37%] vs 115 [30%]), decreased neutrophil count (98 [22%] vs 95 [24%]), thrombocytopenia (95 [21%] vs 70 [18%]), and decreased platelet count (92 [20%] vs 92 [24%]). Serious adverse events occurred in 243 (54%) patients who received atezolizumab plus chemotherapy and 196 (50%) patients who received placebo plus chemotherapy. Treatment-related deaths occurred in nine (2%; acute kidney injury, dyspnoea, hepatic failure, hepatitis, neutropenia, pneumonitis, respiratory failure, sepsis, and thrombocytopenia [n=1 each]) patients who received atezolizumab plus chemotherapy and four (1%; unexplained death, diarrhoea, febrile neutropenia, and toxic hepatitis [n=1 each]) who received placebo plus chemotherapy. INTERPRETATION: Progression-free survival benefit with first-line combination of atezolizumab plus platinum-based chemotherapy did not translate into a significant improvement in overall survival in the ITT population of IMvigor130. Further research is needed to understand which patients might benefit from first-line combination treatment. No new safety signals were observed. FUNDING: F Hoffmann-La Roche.
引用
- Grande E, Arranz JÁ, De Santis M, et al. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. Lancet Oncol. 2023. PMID: 38101433. doi:10.1016/S1470-2045(23)00540-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。